Table 4.
Tumor marker expression level by LMP1 status among EBV+ DLBCL cases.
| EBV+ DLBCL LMP1 expression status |
BCL6 | BLIMP1 | LMO2 | CD30 |
|---|---|---|---|---|
|
| ||||
| Tumor marker scorea, mean (sd) | ||||
| LMP− (n=14) | 0.79 (1.31) | 1.08 (1.44) | 0.93 (1.00) | 0.77 (1.17) |
| LMP+ (n=8) | 0.13 (0.35) | 0.25 (0.71) | 1.38 (1.06) | 3.38 (1.19) |
|
| ||||
| BCL2 | BAX | Cyclin D2 | Cyclin E | |
|
|
||||
| LMP− | 0.92 (1.04) | 1.64 (1.65) | 0.07 (0.27) | 1.71 (1.33) |
| LMP+ | 2.00 (1.31) | 2.86 (0.90) | 0 (0) | 1.50 (1.41) |
|
| ||||
| Ki-67 | FOXP1 | P53 | Survivin | |
|
|
||||
| LMP− | 2.38 (0.65) | 1.07 (1.49) | 0.79 (1.19) | 2.21 (1.48) |
| LMP+ | 2.13 (0.64) | 0.63 (0.74) | 0.75 (0.71) | 3.71 (0.76) |
|
| ||||
| P27 | MMP9 | GAL3 | SKP2 | |
|
|
||||
| LMP− | 0.79 (0.80) | 1.92 (1.75) | 1.08 (1.19) | 0.50 (1.09) |
| LMP+ | 0.38 (0.52) | 2.75 (1.58) | 1.75 (1.75) | 0.25 (0.46) |
|
| ||||
| PKC-beta 2 | MUM1 | cMYC | CD43 | |
|
|
||||
| LMP− | 2.43 (1.55) | 2.79 (1.42) | 2.00 (1.52) | 1.69 (1.97) |
| LMP+ | 4.00 (0) | 2.00 (1.31) | 1.25 (1.39) | 1.25 (1.83) |
|
| ||||
| CD10 | CD44 | CD21 | ||
|
|
||||
| LMP− | 1.29 (1.59) | 2.62 (1.04) | 0 (0) | |
| LMP+ | 0.50 (0.53) | 2.88 (1.46) | 0 (0) | |
a
Tumor marker score 0=0–9%, 1=10–24%, 2=25–49%, 3=50–74% and 4= ≥75% of DLBCL cells stained positive for the marker.